Unstable genes unstable mind: Beyond the central dogma of molecular biology

Medical Hypotheses

Volumn 77, Issue 2, 2011, Pages 165-170

  Hegde, Mahabaleshwar V ^a   Saraph, Arundhati A ^b  

^a BHARATI VIDYAPEETH UNIVERSITY   (India)

^b Research and Innovation Group   (India)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; GLUTAMIC ACID; GLUTAMINE; GLUTATHIONE; PARACETAMOL;

ARTICLE; BRAIN CELL; CAG REPEAT; DISEASE SEVERITY; GENE CONTROL; GENE EXPRESSION; GENETICS; HUMAN; HYPOTHESIS; IN VIVO STUDY; MEDICAL RESEARCH; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PSYCHOSIS; SCHIZOPHRENIA;

ANTICIPATION, GENETIC; GENE EXPRESSION REGULATION; GLUTAMINE; HUMANS; MODELS, NEUROLOGICAL; SCHIZOPHRENIA; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 79960637809     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.03.051     Document Type: Article

References (47)

1. Patrick F., Sullivan, Kenneth S., Kendler, Michael C., Neale Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003, 60:1187-1192.
2. Steven P. Hamilton, schizophrenia candidate genes: Are we really coming up blank?. Am J Psychiatry 2008, 165:420-423.
3. Basset A.S., Honer W.G. Evidence for anticipation in schizophrenia. Am J Hum genet 1994, 54:864-870.
4. Fortune M.T., Kennedy J.L., Vincent J.B. Anticipation and CAG*CTG repeat expansion in schizophrenia and bipolar affective disorder. Curr Psychiatry Rep 2003, 2:145-154.
5. Petronis A., Kennedy J.L. Unstable genes-Unstable mind. Am J Psychiatry 1995, 152:164-172.
6. Chandy K.G., Fantino E. Wittekindt O et al. Isolation of novel potassium channel gene hSKCa3 containing a polymorphic CAG repeat: a candidate for schizophrenia and bipolar disorder?. Mol Psychiatry 1998, 1:32-37.
7. MacDonald A.W. Schulz SC What we know: findings that every theory of schizophrenia should explain. Schizophr Bull. 2009, 35:493-508.
8. Stefanie L Butland, Rebecca S Devon, Yong Huang et al., CAG-encoded polyglutamine length polymorphism in the human genome. BMC Genomic 2007; 8:126. doi:10.1186/1471-2164-8-126.
9. Albanese V. Holbert S. Saada C et al. CAG/CTG and CGG/GCC Repeats in Human Brain Reference cDNAs: Outcome in Searching for New Dynamic Mutations Genomics 1998, 47:414-418.
10. Kortun I.V., Mcmurray C.T. Features of trinucleotide repeat instability in vivo. Cell Research 2008, 18:198-213.
11. Debby Tsuang, Elisabeth W., Almqvist, Hillary Lipe R.N., Franc Strgar, Lilly DiGiacomo Familial Aggregation of Psychotic Symptoms in Huntington's Disease. Am J Psychiatry 2000, 157:1955-1959.
12. Naoto Adachi, Kunimasa Arima, Takashi Asada, et al. Dentatorubral - Pallidoluysian atrophy (DRPLA) presenting with psychosis. J Neuropsychiatry Clin Neurosci 2001, 13:258-260.
13. Joo E.J., Lee J.H., Cannon T.D., Price R.A. Possible association between schizophrenia and a CAG repeat polymorphism in the spinocerebellar ataxia type (SCA1) gene on human chromosome 6p23. Psychiatric Genetics 1999, 9:7-11.
14. Ohi, K., Hashimoto, R., Yasuda, Y et al. TATA box-binding protein gene is associated with risk for schizophrenia, Age at onset and prefrontal function. Genes Brain Behav 2009; 4: 473-480. doi:10.1111/j.1601-183X.2009.00497.x.
15. Imamura A., Tsujita T., Kayashima T. Lack of association between the hKCa3 gene and Japanese schizophrenia patients. Psychiatr Genet 2001, 11:227-229.
16. Ivković M., Ranković A., Tarasjev S. Schizophrenia and polymorphic CAG repeats array of calcium-activated potassium channel (KCNN3) gene in Serbian population. Int J Neurosci 2006, 116:157-164.
17. Kantrowitz J.T., Javitt D.C. Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Clin Schizophr Relat Psychoses 2010, 4:189-200.
18. Daniel C., Javitt Glutamatergic theories of schizophrenia Isr. J Psychiatry Relat Sci 2010, 47:4-16.
19. Kenji Hashimoto, Göran Engberg, Eiji Shimizu1, Conny Nordin, Leif H Lindström, Masaomi Iyo Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients BMC Psychiatry 5 (2005) 6 doi:10.1186/1471-244X-5-6.
20. Théberge J., Robert Bartha R., Drost D.J., et al. Glutamate and glutamine measured with 4.0 T proton MRS in never- treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 2002, 159:1944-1946.
21. Théberge J., Al-Semaan Y., Williamson P., et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0T proton MRS. Am J Psychiatry 2003, 160:2231-2233.
22. Shirayama Y., Obata T., Matsuzawa D. Nonaka H et al. Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary study. Neuroimage 2010, 49:2783-2790.
23. Shulman Y., Grant S., Seres P., Hanstock C., Baker G. And Tibbo P The relation between peripheral and central glutamate and glutamine in healthy male volunteers. J Psychiatry Neurosci 2006, 31:406-410.
24. Peet M. Eicosapentaenoic acid in the treatment of schizophrenia and depression: rationale and preliminary double-blind clinical trial results. Prostaglandins Leukot Essent Fatty Acids. 2003, 69:477-485.
25. Berger G., Wood S., Willard R., et al. Ethyl-eicosapentaenoic acid in first-episode psychosis A1H-MRS study. Neuropsychopharmacology 2008, 33:2467-2473.
26. Tibbo P., Hanstock C., Valiakalayil A., Allen P. 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J Psychiatry 2004, 161:1116-1118.
27. Moriniere S., Saada C. Holbert S et al. Detection of polyglutamine expansion in a new acidic protein: a candidate for childhood onset schizophrenia. Mol Psychiatry 1999, 4:58-63.
28. Jingchun S., Peilin J., Ayman H., et al. Schizophrenia gene networks, pathways, their applications for novel candidate gene selection. PLoS One 2010, 29:5. e11351.
29. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron 2003, 40:881-884.
30. Yevgeny D., Marc Y. Compartmentation of Brain Glutamate Metabolism in Neurons and Glia. J Nutr 2000, 130:1026S-1031S.
31. Bruneau E.G., McCullumsmith R.E., Haroutunian V., Davis K.L., Meador-Woodruff J.H. Increased expression of glutaminase and glutamine synthetase mRNA in the thalamus in schizophrenia. Schizophr Res 2005, 75:27-34.
32. Nanitsos E.K., Nguyen K.T., St'astný F., Balcar V.J. Glutamatergic hypothesis of schizophrenia: involvement of Na+/K+- dependent glutamate transport. J Biomed Sci 2005, 12:975-984.
33. Huerta I., McCullumsmith R. Haroutunian V et al. Expression of excitatory amino acid transporter interacting protein transcripts in the thalamus in schizophrenia. Synapse 2006, 59:394-402.
34. Cherlyn S.Y., Woon P.S., Liu J.J., Ong W.Y., Tsai G.C., Sim K. Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance. Neurosci Biobehav Rev 2010, 34:958-977.
35. Yao J.K., Leonard S., Reddy R. Altered glutathione redox state in schizophrenia. Dis Markers. 2006, 22:83-93.
36. Bauer D., HaroutunianV Meador.-Woodruff.J.H., McCullumsmith R.E. Abnormal glycosylation of EAAT1 and EAAT2 in prefrontal cortex of elderly patients with schizophrenia. Schizophr Res 2010, 117:92-98.
37. Prabakaran S., Swatton J.E., Ryan M.M., et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 2004, 9:684-697.
38. Fullerton J.M., Yash Tiwar, Giti Agah Assessing oxidative pathway genes as risk factors for bipolar disorder. Bipolar Disord 2010, 12:550-556.
39. Ranjekar P.K., Hinge A., Hegde M.V., et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 2003, 121:109-112.
40. Reddy R.D., Yao J.K. Free radical pathology in schizophrenia. Prostaglandins Leukot Essent Fatty acids 1996, 55:33-34.
41. Gysin R., Kraftsik R., Sandell J., et al. Negative Correlation between Brain Glutathione Level and Negative Symptoms in Schizophrenia: A 3T 1H-MRS Study. PLoS One 2008, 3:e1944.
42. Tosic M., Ott J., Barral S., Bovet P. Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am J Hum Genet 2000, 79:586-592.
43. Arvindakshan M., Ghate M., Ranjekar P.K., Evans D.R., Mahadik S.P. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res 2003, 62:195-204.
44. Berk M., Copolov D., Dean O., et al. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008, 64:361-368.
45. S.P. Mahadik, M. Mulchandani, M.V. Hegde, Cultural and socioeconomic differences in dietary intake of the essential fatty acids and antioxidants-effects on the outcome in phospholipid spectrum disorders in psychiatry, in: D. Horrobin, A.L. Glen, M. Peet, Marius Press, Carnforth UK, 1999, 167-179.
46. Horrobin D.F. Schizophrenia: The illness that made us human Med Hypotheses 1998, 50:269-288.
47. Djian P., Hancock J.M., Chana H.S. Codon repeats in genes associated with human diseases: fewer repeats in the genes of nonhuman primates and nucleotide substitutions concentrated at the sites of reiteration. Proc Natl Acad Sci U S A. 1996, 3:417-421.